Pharma: Other News To Note
• Ipsen SA, of Paris, said Health Canada granted marketing authorization for Dysport (botulinum toxin Type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines in adults younger than 65.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries, please contact Tyler Beatty:
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
tyler.beatty@thomsonreuters.com
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
tyler.beatty@thomsonreuters.com
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2014 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter